Dare Bioscience's Total Assets for the quarter that ended in Mar. 2024 was $13.01 Mil.
During the past 12 months, Dare Bioscience's average Total Assets Growth Rate was -11.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 55.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 57.30% per year.
During the past 12 years, Dare Bioscience's highest 3-Year average Total Assets Growth Rate was 59.40%. The lowest was -24.50%. And the median was 44.50%.
The historical data trend for Dare Bioscience's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Dare Bioscience's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (NAS:DARE) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Dare Bioscience's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Dare Bioscience Total Assets Related Terms
Thank you for viewing the detailed overview of Dare Bioscience's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Dare Bioscience (Dare Bioscience) Business Description
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARE has been successfully added to your 